Ex-Novartis exec joins Ipsen as President, Head of Specialty Care
Harout Semerjian has joined French pharma firm Ipsen as President, Head of Specialty Care International Region & Global Franchises, the company has announced.
Semerjian was confirmed for the role at the same time the company announced that Dr Sotirios Stergiopoulos has also joined Ipsen as its Senior Vice President and Head of Global Medical Affairs.
Semerjian, who also takes on membership of the Executive Leadership Team at Ipsen, brings over 23 years of experience to the position. He joins the company from Novartis, a brand he served for 17 years, most recently as Senior Vice President and Global Launch Head of ribociclib. During his tenure, he has held responsibility for operations across the US, Canada, and EMEA.
Semerjian will report directly to Ipsen CEO David Meek, who commented on his appointment by saying, “I am delighted to welcome Harout Semerjian to Ipsen. Harout brings extensive leadership experience in oncology and has achieved success across a diverse range of markets including the U.S., Europe and the Middle East. He will be a tremendous asset to Ipsen, particularly as we accelerate our growth across markets and strengthen our focus on speciality care and oncology.”
Ipsen and Medision Pharma have announced that Health Canada has approved Bylvay (odevixibat) for the …
Ipsen has announced that the US Food and Drug Administration (FDA) has approved Sohonos (palovarotene) …